title: [Monitoring AML1-ETO mRNA levels by real-time quantitative RT-PCR in t(8;21) acute myeloid leukemia patients after hematopoietic stem cell transplantation].
abstract: OBJECTIVE
  To evaluate the value of real time quantitative RT-PCR (Q-PCR) for monitoring AML1-ETO mRNA levels in AML1-ETO(+) acute myeloid leukemia (AML) patients following allogeneic hematopoietic stem cell transplantation (allo-HSCT).
  
  
  METHODS
  Quantification of AML1-ETO(+) mRNA was performed serially on bone marrow samples from 17 patients with AML1-ETO(+) AML after HSCT. Q-PCR used the TagMan probe system. The AML1-ETO mRNA level was normalized by control gene abl. Cytogenetic response was evaluated by fluorescent in situ hybridization (FISH).
  
  
  RESULTS
  The reproducible sensitivity of Q-PCR was 5 copies. Out of 16 patients who achieved sustained complete cytogenetic response (CCyR), one each died of graft-versus-host disease and infection. The median AML1-ETO mRNA levels in the rest of 14 CCyR patients were 0 (0 - 0.740), 0.026 (0 - 2.900), 0.039 (0 - 3.300) at +1, +2, +3 month post allo-HSCT, respectively and in 5 CCyR patients beyond 1 year following allo-HSCT (median follow-up 685 days) was 0.078 (0.003 - 0.120). The AML1-ETO mRNA levels in one relapsed patient were 0, 9.8 and 5.6 at +1, +2 and +3 month post allo-HSCT, respectively and hematological relapse occurred at +110 day, when the AML1-ETO mRNA levels increased dramatically from 5.600 to 390.000.
  
  
  CONCLUSIONS
  Q-PCR is a sensitive technique in monitoring AML1-ETO(+) AML patients post allo-HSCT. Persistence of a low level within one year after allo-HSCT does not mean at risk of relapse. It is necessary to dynamic monitoring AML1-ETO mRNA after remission in t(8;21) AML patients.
authors.affiliation: Institute of Hematology, People's Hospital of Peking University, Beijing 100044, China.
authors.forename: Zhi-Dong
authors.initials: ZD
authors.lastname: Wang
authors.forename: Ya-Zhen
authors.initials: YZ
authors.lastname: Qin
authors.forename: Yan-Rong
authors.initials: YR
authors.lastname: Liu
authors.forename: Lan-Ping
authors.initials: LP
authors.lastname: Xu
authors.forename: Dai-Hong
authors.initials: DH
authors.lastname: Liu
authors.forename: Kai-Yan
authors.initials: KY
authors.lastname: Liu
authors.forename: Xiao-Jun
authors.initials: XJ
authors.lastname: Huang
mesh_terms: D000293:Adolescent; D000328:Adult; D050676:Core Binding Factor Alpha 2 Subunit / Q000235:genetics / Q000378:metabolism*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000378:metabolism* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D015514:Oncogene Proteins, Fusion / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics; D000075142:RUNX1 Translocation Partner 1 Protein; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods*; D055815:Young Adult
chemical_list: C107844:AML1-ETO fusion protein, human; D050676:Core Binding Factor Alpha 2 Subunit; D015514:Oncogene Proteins, Fusion; D012333:RNA, Messenger; D000075142:RUNX1 Translocation Partner 1 Protein